The U.S. Securities and Exchange Commission leveled charges at a former Sangamo Therapeutics executive and others for an insider-trading scheme that netted more than $1.5 million in “illegal profits.”
Cambridge, Mass.-based bluebird bio’s LentiGlobin gene therapy is increasing hemoglobin levels in anemia patients battling sickle cell disease and beta thalassemia, which reduces the need for blood transfusions in those patients.